Amplitude Surgical SA (EPA:AMPLI)

France flag France · Delayed Price · Currency is EUR
6.05
-0.05 (-0.82%)
Mar 28, 2025, 5:35 PM CET
77.94%
Market Cap 290.23M
Revenue (ttm) 108.47M
Net Income (ttm) 1.09M
Shares Out 47.97M
EPS (ttm) 0.02
PE Ratio 266.79
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 292
Average Volume 12,195
Open 6.10
Previous Close 6.10
Day's Range 6.05 - 6.10
52-Week Range 2.70 - 6.15
Beta 0.44
RSI 84.11
Earnings Date Mar 26, 2025

About Amplitude Surgical

Amplitude Surgical SA designs, develops, and markets products for orthopedic surgery in France and internationally. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It also offers AMPLIVISION, a computer-assisted surgery system; the i.M.A.G.E., a single-use made-to-measure instrument system; and E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. The company ex... [Read more]

Sector Healthcare
Founded 1997
Employees 389
Stock Exchange Euronext Paris
Ticker Symbol AMPLI
Full Company Profile

Financial Performance

In 2024, Amplitude Surgical's revenue was 106.02 million, an increase of 5.81% compared to the previous year's 100.20 million. Earnings were 1.53 million, a decrease of -96.11%.

Financial Statements

News

Zydus Life shares drop nearly 3% as UBS maintains ‘Sell’ rating

Zydus Life saw a 2.9% decline in its share price after UBS reaffirmed its ‘Sell’ rating, setting a target price of ₹850. As of 9:36 AM, the shares were trading 2.80% lower at Rs 874.65. The rating dow...

18 days ago - Business Upturn

Zydus Life share price: Bank of America sees 10% potential upside on medtech expansion

Bank of America (BofA) Securities has maintained a ‘Neutral’ rating on Zydus Life, with a target price of ₹1,040, indicating potential upside from the current market price of ₹901.50 (as of March 11)....

18 days ago - Business Upturn

Zydus Life share price: UBS sees downside, maintains ‘Sell’ with Rs 850 target

UBS has maintained a ‘Sell’ rating on Zydus Life, setting a target price of ₹850, indicating a downside potential from the current market price of ₹901.50 (as of March 11). The brokerage expressed con...

18 days ago - Business Upturn

Stock Market news: Bharti Airtel, Zydus Life, Bharat Forge, Tata Motors, Sun Pharma among stocks to watch today on brokerage updates

Several stocks are in focus today following fresh brokerage reports. Key updates include Bharti Airtel’s tie-up with SpaceX’s Starlink, Zydus Life’s acquisition of Amplitude Surgical, and varied views...

18 days ago - Business Upturn

Zydus Life in negotiations to buy French medtech firm

Zydus Lifesciences announced it is negotiating to acquire a majority stake in French medtech firm Amplitude Surgical for approximately Rs 2,500 crore. The acquisition aims to boost Zydus's global medt...

18 days ago - The Times of India

Zydus Lifesciences to acquire 85.6% stake in Amplitude Surgical SA for €256.8 million

Zydus Lifesciences Limited has announced its acquisition of an 85.6% controlling stake in Amplitude Surgical SA, a leading French MedTech company specializing in orthopedic solutions. This strategic m...

19 days ago - Business Upturn